Pleura and Peritoneum最新文献

筛选
英文 中文
Implementation of ERAS guidelines in patients undergoing CRS and HIPEC: need for multicentre trial 在接受 CRS 和 HIPEC 治疗的患者中实施 ERAS 指南:需要进行多中心试验
IF 1.8
Pleura and Peritoneum Pub Date : 2023-12-20 DOI: 10.1515/pp-2023-0022
C. Iavazzo, I. Gkegkes, J. Spiliotis
{"title":"Implementation of ERAS guidelines in patients undergoing CRS and HIPEC: need for multicentre trial","authors":"C. Iavazzo, I. Gkegkes, J. Spiliotis","doi":"10.1515/pp-2023-0022","DOIUrl":"https://doi.org/10.1515/pp-2023-0022","url":null,"abstract":"","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"111 21","pages":""},"PeriodicalIF":1.8,"publicationDate":"2023-12-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138954045","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Second annual report from the ISSPP PIPAC database ISSPP PIPAC 数据库第二次年度报告
IF 1.8
Pleura and Peritoneum Pub Date : 2023-12-13 DOI: 10.1515/pp-2023-0047
Michael Bau Mortensen, Francesco Casella, Özgül Düzgün, Olivier Glehen, Peter Hewett, Martin Hübner, Magnus Skov Jørgensen, Alfred Königsrainer, Miguel Marin, M. Pocard, Günther Rezniczek, Jimmy So, C. Fristrup
{"title":"Second annual report from the ISSPP PIPAC database","authors":"Michael Bau Mortensen, Francesco Casella, Özgül Düzgün, Olivier Glehen, Peter Hewett, Martin Hübner, Magnus Skov Jørgensen, Alfred Königsrainer, Miguel Marin, M. Pocard, Günther Rezniczek, Jimmy So, C. Fristrup","doi":"10.1515/pp-2023-0047","DOIUrl":"https://doi.org/10.1515/pp-2023-0047","url":null,"abstract":"Abstract Objectives To monitor the results of PIPAC directed therapy based on data from the International Society for the Study of the Pleura and Peritoneum (ISSPP) PIPAC database. Methods Analysis of data from patients entered between June 15th, 2020, and February 28th, 2023. Results Twelve centers reported 2,456 PIPAC procedures in 809 patients (median 2, range 1–18) with peritoneal metastasis (PM) from different primary tumors. Approximately 90 % had systemic chemotherapy prior to PIPAC. Twenty-eight percent were treated in prospective protocols. Overall non-access rate was 3.5 %. Concomitant surgical procedures were performed during PIPAC in 1.6 % of the patients. Median length of stay was 2 days. A total of 95 surgical complications were recorded, but only 22 % of these were graded ≥3b. Seventeen-hundred-and-three adverse events were noted, and 8 % were classified ≥3. The rate of complete or major histological response (peritoneal regression grade score, PRGS≤2) increased between the first and the third PIPAC in the group of patients who were evaluated by PRGS, and a PRGS ≤2 or a reduction of the mean PRGS of at least 1 between first and third PIPAC were observed in 80 %. Disease progression (50 %) or technical issues (19 %) were the most important reasons for stopping PIPAC treatment. Median overall survival from first PIPAC directed treatment varied from 10.7 months (CI 8.7–12.5) in gastric cancer to 27.1 months (16.4–50.5) in mesothelioma. Conclusions The ISSPP PIPAC database provides substantial real-world data supporting the use of PIPAC directed therapy in patients with PM from different primary tumors.","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"49 3","pages":""},"PeriodicalIF":1.8,"publicationDate":"2023-12-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"138633039","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
What is long-term survival in patients with peritoneal metastasis from gastric, pancreatic, or colorectal cancer? A study of patients treated with systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC) 胃癌、胰腺癌或结直肠癌腹膜转移患者的长期生存率如何?对接受全身化疗和腹腔内加压气溶胶化疗 (PIPAC) 患者的研究
IF 1.8
Pleura and Peritoneum Pub Date : 2023-12-01 DOI: 10.1515/pp-2023-0038
Charlotte G. Kryh-Jensen, C. Fristrup, Alan P. Ainsworth, S. Detlefsen, Michael B. Mortensen, Per Pfeiffer, L. Tarpgaard, M. Graversen
{"title":"What is long-term survival in patients with peritoneal metastasis from gastric, pancreatic, or colorectal cancer? A study of patients treated with systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC)","authors":"Charlotte G. Kryh-Jensen, C. Fristrup, Alan P. Ainsworth, S. Detlefsen, Michael B. Mortensen, Per Pfeiffer, L. Tarpgaard, M. Graversen","doi":"10.1515/pp-2023-0038","DOIUrl":"https://doi.org/10.1515/pp-2023-0038","url":null,"abstract":"Abstract Objectives A definition of long-term survival (LTS) in patients with peritoneal metastasis (PM) from gastric cancer (GC), pancreatic cancer (PC) or colorectal cancer (CRC) treated with systemic chemotherapy and pressurized intraperitoneal aerosol chemotherapy (PIPAC) is lacking. We aimed to define LTS and investigate characteristics and treatment response in patients who reached LTS in data from two prospective trials. Methods Retrospective study of patients with GC-, PC-, or CRC-PM from the prospective PIPAC-OPC1 and PIPAC-OPC2 studies. The definition of LTS was based on published systematic reviews and randomized controlled trials. LTS was defined at the time point where 25 % of the patients were alive in these studies. Histology based response was evaluated by the mean Peritoneal Regression Grading Score (PRGS) using biopsies obtained prior to PIPAC 3, and defined by a mean PRGS of ≤2.0 or a decrease of mean PRGS of ≥1, compared to baseline. Results LTS was defined at 21 (GC), 15 (PC), and 24 (CRC) months. Fifty-one (47.2 %) patients (nine GC, 17 PC, 25 CRC) reached LTS calculated from the date of PM diagnosis. All but one received palliative chemotherapy before PIPAC, and 37 % received bidirectional treatment. More than 90 % of the LTS patients had response according to PRGS. The mOS from PIPAC 1 was 23.3, 12.4, and 28.5 months for GC, PC, and CRC LTS patients. Conclusions Patients with PM from GC, PC, and CRC treated with systemic chemotherapy and PIPAC can reach LTS and most show histological response. Causality must be further investigated.","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"990 1","pages":"147 - 155"},"PeriodicalIF":1.8,"publicationDate":"2023-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139019425","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Genital cutaneous necrosis: a delayed sequela of intraperitoneal Mitomycin-c 生殖器皮肤坏死:腹膜内注射丝裂霉素c的延迟后遗症
Pleura and Peritoneum Pub Date : 2023-10-13 DOI: 10.1515/pp-2023-0021
Sage A. Vincent, Meghan Maceyko, Peter J. Altshuler, Zachary Davis, J. Ryan Mark, Paul H. Chung, Wilbur B. Bowne
{"title":"Genital cutaneous necrosis: a delayed sequela of intraperitoneal Mitomycin-c","authors":"Sage A. Vincent, Meghan Maceyko, Peter J. Altshuler, Zachary Davis, J. Ryan Mark, Paul H. Chung, Wilbur B. Bowne","doi":"10.1515/pp-2023-0021","DOIUrl":"https://doi.org/10.1515/pp-2023-0021","url":null,"abstract":"","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"251 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-10-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135805251","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Abdominal tuberculosis mimicking peritoneal metastasis. 模拟腹膜转移的腹部结核。
IF 1.8
Pleura and Peritoneum Pub Date : 2023-09-01 DOI: 10.1515/pp-2023-0012
Ragad I Al Jazzar, Zeinah Sulaihim, Ahmad Alkhiary, Nayef Alzahrani
{"title":"Abdominal tuberculosis mimicking peritoneal metastasis.","authors":"Ragad I Al Jazzar, Zeinah Sulaihim, Ahmad Alkhiary, Nayef Alzahrani","doi":"10.1515/pp-2023-0012","DOIUrl":"https://doi.org/10.1515/pp-2023-0012","url":null,"abstract":"Peritoneal tuberculosis is a rare form of extrapulmonary tuberculosis. This challenge is attributed to its great mimicry of other peritoneal disease processes along with its nonspeci fi c clinical presentation. We report a case of a 60-year old man, known case of rectosigmoid cancer with liver and lung nodules. Status post low anterior resection,","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 3","pages":"139-140"},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469162/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10137336","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic value of preoperative serological biomarkers in patients undergoing cytoreductive surgery for ovarian cancer peritoneal metastases. 术前血清学生物标志物在卵巢癌腹膜转移患者行细胞减缩手术中的预后价值。
IF 1.8
Pleura and Peritoneum Pub Date : 2023-09-01 DOI: 10.1515/pp-2022-0199
Charif Khaled, Antoine El Asmar, Omar Raisi, Michel Moreau, Laura Polastro, Isabelle Veys, Florin C Pop, Vincent Donckier, Gabriel Liberale
{"title":"Prognostic value of preoperative serological biomarkers in patients undergoing cytoreductive surgery for ovarian cancer peritoneal metastases.","authors":"Charif Khaled,&nbsp;Antoine El Asmar,&nbsp;Omar Raisi,&nbsp;Michel Moreau,&nbsp;Laura Polastro,&nbsp;Isabelle Veys,&nbsp;Florin C Pop,&nbsp;Vincent Donckier,&nbsp;Gabriel Liberale","doi":"10.1515/pp-2022-0199","DOIUrl":"https://doi.org/10.1515/pp-2022-0199","url":null,"abstract":"<p><strong>Objectives: </strong>Peritoneal metastases of ovarian cancer (PMOC) are common at initial presentation. Cytoreductive surgery (CRS) of curative intent has been proven to be efficient in increasing the overall survival (OS) and the disease-free survival (DFS) of these patients. Nevertheless, CRS is associated with high postoperative morbidity, which makes patient selection a major concern. Appropriate prognostic factors that can predict patient outcomes after surgery are still lacking. Preoperative biomarkers and their ratios have been shown to be predictive of patient prognosis for various solid tumors. We aimed to study their correlation with the prognosis of patients undergoing CRS for PMOC.</p><p><strong>Methods: </strong>This retrospective study included patients with PMOC operated by CRS. Preoperative biomarkers and other clinicopathological characteristics were studied to determine their prognostic value in terms OS and DFS.</p><p><strong>Results: </strong>216 patients were included. Patients with preoperative hemoglobin (Hb) <11.7 g/dL had a poorer prognosis in terms of OS (p=0.0062) and DFS (p=0.0077). Additionally, increased neutrophil-to-lymphocyte ratio (NLR), monocyte-to-lymphocyte ratio (MLR) >0.32, and platelet-to-lymphocyte ratio (PLR) >214.5 were associated with worse OS (p=0.022, p=0.0028, and p=0.0018, respectively) and worse DFS (p=0.028, p=0.003, and p=0.019, respectively). Multivariate analysis showed that the variables mentioned above were independent predictive factors for OS and DFS.</p><p><strong>Conclusions: </strong>Preoperative Hb level, NLR, MLR, and PLR are prognostic factors for OS and DFS in PMOC patients operated by curative CRS.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 3","pages":"133-138"},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469179/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10142844","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
Investigation of the effectiveness of hyperthermic intraperitoneal chemotherapy in experimental colorectal peritoneal metastasis model. 腹腔热化疗对实验性大肠癌腹膜转移模型的影响。
IF 1.8
Pleura and Peritoneum Pub Date : 2023-09-01 DOI: 10.1515/pp-2023-0002
Berke Manoğlu, Tuğba Yavuzşen, Safiye Aktaş, Zekiye Altun, Osman Yılmaz, Özde Elif Gökbayrak, Aylin Erol
{"title":"Investigation of the effectiveness of hyperthermic intraperitoneal chemotherapy in experimental colorectal peritoneal metastasis model.","authors":"Berke Manoğlu,&nbsp;Tuğba Yavuzşen,&nbsp;Safiye Aktaş,&nbsp;Zekiye Altun,&nbsp;Osman Yılmaz,&nbsp;Özde Elif Gökbayrak,&nbsp;Aylin Erol","doi":"10.1515/pp-2023-0002","DOIUrl":"https://doi.org/10.1515/pp-2023-0002","url":null,"abstract":"<p><strong>Objectives: </strong>In our study, we aimed to (1) create a peritoneal metastasis (PM) model in nude mice, administer intraperitoneal chemotherapy using the peritoneal infusion pump we developed in this model, and (2) compare the efficacy of intraperitoneal chemotherapy using various drugs at different temperatures.</p><p><strong>Methods: </strong>The peritoneal metastasis model was established in nude mice using the CC531 colon carcinoma cell line. Models with peritoneal metastasis (PM) were randomized into four groups of seven animals each: Group 1, control group (n=7); Group 2, normothermic intraperitoneal chemotherapy (NIPEC) with mitomycin C(MMC) (n=7); Group 3, hyperthermic intraperitoneal chemotherapy (HIPEC) with mitomycin C (n=7), and Group 4, NIPEC with 5-fluorouracil (5-FU).</p><p><strong>Results: </strong>Tumor development was achieved in all animals. While the tumor burden decreased significantly in the treatment Group 3 (p=0.034), no significant difference was found in the other groups. In the PM mouse model, hyperthermic intraperitoneal administration of MMC had the highest tumoricidal effect.</p><p><strong>Conclusions: </strong>Our PM model provided a good opportunity to examine the efficacy of HIPEC and intraperitoneal infusion pump (IPIP). In future studies, we plan to evaluate efficacies of different drugs in the PM models we have created.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 3","pages":"123-131"},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469180/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10524103","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Early postoperative CRP predicts major complications following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC). 术后早期CRP可预测细胞减少手术(CRS)和腹腔热化疗(HIPEC)后的主要并发症。
IF 1.8
Pleura and Peritoneum Pub Date : 2023-09-01 DOI: 10.1515/pp-2022-0203
Akash Kartik, Catharina Müller, Miklos Acs, Pompiliu Piso, Patrick Starlinger, Thomas Bachleitner-Hofmann, Travis E Grotz
{"title":"Early postoperative CRP predicts major complications following cytoreductive surgery (CRS) and hyperthermic intraperitoneal chemotherapy (HIPEC).","authors":"Akash Kartik,&nbsp;Catharina Müller,&nbsp;Miklos Acs,&nbsp;Pompiliu Piso,&nbsp;Patrick Starlinger,&nbsp;Thomas Bachleitner-Hofmann,&nbsp;Travis E Grotz","doi":"10.1515/pp-2022-0203","DOIUrl":"https://doi.org/10.1515/pp-2022-0203","url":null,"abstract":"<p><strong>Objectives: </strong>Cytoreductive surgery (CRS) and heated intraperitoneal chemotherapy (HIPEC) is associated with significant postoperative complications. Early detection of at-risk patients may lead to improved outcomes. The role of C-reactive protein (CRP) in predicting postoperative complications has only been recently investigated.</p><p><strong>Methods: </strong>Postoperative complications were categorized according to Clavien-Dindo classification and further divided into minor (Grade <3) and major complications (Grade ≥3A). Absolute CRP counts (mg/L) on postoperative days (POD) 1-7, and proportional change in CRP was compared and the area under (AUC) receiver operating characteristics (ROC) curve was calculated. Univariate and multivariate analysis was performed. Significant findings were externally validated.</p><p><strong>Results: </strong>Twenty-five percent of patients experienced one or more major complications. A CRP level of ≥106 mg/L on POD 2 and 65.5 mg/L on POD 4 were significantly associated with an increased risk of major complications with an AUC of 0.658 and 0.672, respectively. The proportional increase in CRP between POD 1 and 4 (ΔCRP POD 1/4) at a cut-off of 30 % had the best AUC of 0.744 and was the only independent risk factor for major complications (p<0.0001) on multivariate analysis. ∆CRP had an AUC of 0.716 (p=0.002) when validated in an independent database.</p><p><strong>Conclusions: </strong>CRP can be used in a variety of ways to predict major complications after CRS and HIPEC. However, the ∆CRP POD 1/4>30 % is the best indicator of major complications. Serial CRP measurements in the early postoperative period may lead to early detection of patients at risk of major complications allowing for alternative management strategies to improve outcomes.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 3","pages":"113-121"},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10468822/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10142843","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Embryological, anatomical and clinical considerations on pleuroperitoneal communication. 胸膜-腹膜沟通的胚胎学、解剖学和临床考虑。
IF 1.8
Pleura and Peritoneum Pub Date : 2023-09-01 DOI: 10.1515/pp-2023-0013
Christodoulos Chatzigrigoriadis, Anastasios Goulioumis, Despoina Sperdouli, Kostis Gyftopoulos
{"title":"Embryological, anatomical and clinical considerations on pleuroperitoneal communication.","authors":"Christodoulos Chatzigrigoriadis,&nbsp;Anastasios Goulioumis,&nbsp;Despoina Sperdouli,&nbsp;Kostis Gyftopoulos","doi":"10.1515/pp-2023-0013","DOIUrl":"https://doi.org/10.1515/pp-2023-0013","url":null,"abstract":"<p><p>The pleural and peritoneal cavity share many related features due to their common celomic origin. Normally these two spaces are completely separated with the development of the diaphragm. Defects in diaphragm morphogenesis may result in congenital diaphragmatic hernias, which is the most known form of communication between the pleural and peritoneal cavity. However, in several cases, findings of pleuroperitoneal communication (PPC) have been described in adults through an apparently intact diaphragm. In this comprehensive review we systematically evaluate clinical scenarios of this form of \"unexpected\" PPC as reported in the literature and focus on the possible mechanisms involved.</p>","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"8 3","pages":"101-111"},"PeriodicalIF":1.8,"publicationDate":"2023-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469182/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10151308","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Frontmatter 头版头条
Pleura and Peritoneum Pub Date : 2023-08-31 DOI: 10.1515/pp-2023-frontmatter3
{"title":"Frontmatter","authors":"","doi":"10.1515/pp-2023-frontmatter3","DOIUrl":"https://doi.org/10.1515/pp-2023-frontmatter3","url":null,"abstract":"","PeriodicalId":20231,"journal":{"name":"Pleura and Peritoneum","volume":"99 1","pages":"0"},"PeriodicalIF":0.0,"publicationDate":"2023-08-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135890677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
相关产品
×
本文献相关产品
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信